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Abstract
Background: Treatment outcomes for multidrug-resistant Mycobacterium Tuberculosis (MDRTB) are generally poor
compared to drug sensitive disease. We sought to estimate treatment outcomes and identify risk factors associated with
poor outcomes in patients with MDRTB.
Methodology/Principal Findings: We performed a systematic search (to December 2008) to identify trials describing
outcomes of patients treated for MDRTB. We pooled appropriate data to estimate WHO-defined outcomes at the end of
treatment and follow-up. Where appropriate, pooled covariates were analyzed to identify factors associated with worse
outcomes. Among articles identified, 36 met our inclusion criteria, representing 31 treatment programmes from 21
countries. In a pooled analysis, 62% [95% CI 57–67] of patients had successful outcomes, while 13% [9–17] defaulted, 11%
[9–13] died, and 2% [1–4] were transferred out. Factors associated with worse outcome included male gender 0.61 (OR for
successful outcome) [0.46–0.82], alcohol abuse 0.49 [0.39–0.63], low BMI 0.41[0.23–0.72], smear positivity at diagnosis 0.53
[0.31–0.91], fluoroquinolone resistance 0.45 [0.22–0.91] and the presence of an XDR resistance pattern 0.57 [0.41–0.80].
Factors associated with successful outcome were surgical intervention 1.91 [1.44–2.53], no previous treatment 1.42 [1.05–
1.94], and fluoroquinolone use 2.20 [1.19–4.09].
Conclusions/Significance: We have identified several factors associated with poor outcomes where interventions may be
targeted. In addition, we have identified high rates of default, which likely contributes to the development and spread of
MDRTB.
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Introduction
Multidrug-Resistant Tuberculosis (MDRTB) refers to Mycobac-
terium tuberculosis (TB) strains with in vitro resistance to the two most
effective anti-tuberculosis drugs, isoniazid (INH) and rifampin
(RFP). MDRTB has become a major barrier to achieving
successful control of TB, as therapy is less effective, associated
with more adverse events and is more costly to treat when
compared with standard first line therapy. According to a recent
WHO report, approximately 490,000 MDRTB cases occur
globally every year, corresponding to approximately 4.8% of the
world’s TB cases [1,2]. The importance of addressing drug
resistant TB is further amplified by more recent reports on
extensively drug resistant TB (XDRTB) [3], which represented 7%
of MDR isolates referred to supranational reference laboratories
from 2000–2004 [1].
Inadequate treatment of MDRTB can lead to worse patient
outcomes, while increasing the risk of extensive drug resistance
[4–6]. Guidelines for the management of MDRTB have been
developed over the past decade, but there is little evidence based
on randomized controlled trials to support current recommen-
dations [7,8]. Moreover, treatment strategies have varied
significantly and are difficult to compare between populations
[8,9]. This lack of evidence reflects a lack of political and
financial will, in part from the perception that MDRTB is of
limited epidemiological importance [7]. It also reflects the
limited number of second line drugs that are available and the
unequal distribution of access depending on local resources. The
recent recognition of the increasing magnitude of MDRTB,
along with the poor prognosis of XDRTB has created the
impetus for a more evidence-based approach to the treatment of
MDRTB.
Recently, standardized definitions were established to allow
comparison between treatment groups and facilitate the develop-
ment of a more evidence-based approach [9,10]. We therefore
decided to complete a systematic review of MDRTB treatment
regimens. Where appropriate, we performed a meta-analysis to
explore associations between MDRTB treatment outcomes and
the clinical and microbiological factors that influence outcome.
We aimed to identify all the published literature and to establish
the best possible evidence base of clinical and microbiological
predictors of treatment response.
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Search strategy
Several search strategies were used to identify potentially
relevant studies. Search strategy was developed by the investiga-
tors (Johnston and Shahidi) with consultation of a medical
librarian.
1. A systematic search was conducted to identify eligible studies in
the following databases: EMBASE (1980 to Week 50, 2008),
MEDLINE (1965 to Week 50, 2008), International Pharma-
ceutical Abstracts (1970 to November 2008) and BIOSIS (1969
to Week 50, 2008). Keywords included tuberculosis, TB,
multi$, drug$, multidrug, multi-drug, MDRTB, MDR TB,
MDR-TB, extensively drug resistant, extensively drug-resistant,
XDRTB, XDR TB, XDR-TB, drug resistant tuberculosis.
2. Key word search was conducted in EBM Reviews - Cochrane
Database of Systematic Review, Database of Abstracts of
Reviews of Effects, and Cochrane Central Register of
Controlled Trials (all to 4th Quarter 2008). Citations were
reviewed, revealing no systematic reviews on this subject.
3. Keyword and title search of Web of Science was performed
using the terms tuberculosis, TB, tb, multiple drug resistant,
multiple drug resistance, multi-drug resistance, multi-drug
resistant, multi-drug-resistant, drug resistant, MDR, MDRTB,
extensively drug resistant, XDRTB.
4. Hand searching of the following journals: International Journal of
Tuberculosis and Lung Disease, Chest, American Journal of
Respiratory & Critical Care Medicine, and Clinical Infectious Disease.
5. Bibliographies of full text articles were examined for eligible
studies.
6. Results were limited to English articles. Abstracts were
included in search results.
Selection of Studies
Studies obtained from the literature search were checked by title
and citation. If an article appeared relevant, the abstract was
reviewed. Relevant abstracts were examined in full text. Inclusion
criteria were as follows: an original study; reported in English;
reported treatment outcomes in a population of adult, culture-
confirmed MDRTB patients; reported outcomes presented in a
format allowing for comparison with other studies. Exclusion
criteria were as follows: exclusive surgical series; exclusive use of
first-line therapy in the treatment protocol.
Validity assessment
Studies were assessed for quality, with only high quality studies
included for analysis. High quality studies reported outcomes on at
least 10 patients; were prospective cohort, retrospective consecu-
tive cohort, consecutive case control or randomized control in
design; reported an average treatment duration of $12 months
within an average follow-up duration $18 months; reported basic
demographic data; reported less than 1/3 default or lost to follow-
up. When study populations overlapped, we included the more
recent and larger study population in the analysis. If the smaller
population provided data on an outcome or variable not reported
in the larger study, results were included for that specific variable.
Outcome measures
Measured outcomes reflect the definitions proposed by Laserson
et al., and published in recent WHO guidelines [9,10]. Successful
outcomes included patients meeting the definition of Cure or
Treatment Completed. Unsuccessful outcomes included patients
meeting the definition of Death, Defaulted, Failed or Transferred Out.
When follow-up data was used, relapse was included as an
unsuccessful outcome. To homogenize data, end-of-treatment
(EOT) and follow-up (FUP) outcomes were separated for analysis.
FUP outcomes refer to post-treatment follow-up, with follow-up
duration measured in months. If studies were unable to meet
WHO definitions, reviewers established outcomes to reflect these
definitions. Certain studies reported data that precluded the use of
WHO outcome definitions, and were not included for analysis.
Several variables–including co-morbidities, demographic vari-
ables, microbiological profile, disease presentation and disease
characteristics—were collected for outcome analysis. Analysis of
these variables pooled both EOT and FUP outcomes given the
paucity of homogenous data for individual variables. Where
appropriate we contacted investigators for additional data as well
as for clarification of their findings.
Data extraction and statistical analysis
Data abstraction was performed by two reviewers using a
standardized abstraction form. When there was disagreement, the
relevant paper was reviewed and differences were resolved by
consensus. Microsoft Excel (version 12.0), STATSDirect version
2.7.6 (StatsDirect Ltd, Cheshire, UK), and STATA version 10.0
(STATA Corporation, College Station, Texas) software were used
for data entry and analysis. Study characteristics and treatment
outcomes were summarized in tables. Data related to treatment
outcomes were pooled from published studies as described above.
We pooled the proportion of successful outcome, death, default,
transfer of care, and failure across studies using a random-effects
meta-analysis. Heterogeneity of studies was estimated by calculat-
ing I
2 and Cochrane p values. The heterogeneity of binary
covariates was estimated through p values. The overall effect of the
dichotomous data was carried out by using a random effects
analysis because of study heterogeneity (I
2 .50%, p,0.05) and
measured by odds ratio with 95% confidence intervals [95%CI].
Results
We identified 9835 citations from our initial electronic database
search. Of these, 116 articles were identified for full text review. A
further 17 articles were identified through manual search,
bibliographic search, and reviewer suggestions. Of the 133 articles
reviewed in full text, 36 articles, representing 31 distinct patient
populations were analyzed based on our a priori inclusion-exclusion
criteria and quality assessment [11–46]. Ninety-four studies were
removed prior to analysis: 36 lacked adequate data on the patient
population or outcomes; 17 evaluated an inappropriate population
or overlapped with a larger study population; 5 reported outcomes
based on first line therapy alone; 22 did not meet criteria for
treatment duration or follow-up; 9 reported more than one-third
default or loss to follow-up; 5 reported outcomes on ,10 patients;
and 3 were excluded based on study design (Figure 1).
The 36 articles chosen for review reported treatment outcomes
on 31 study populations from 21 countries on 5 continents
(Table 1). The study periods ranged from 1973 to 2006. The
majority were retrospective chart reviews, with five prospective
cohorts [17,28,37,42,43] and one retrospective case control [32].
The average study population (range) was 210 (24–1407). The
majority of patients were male, with a mean of 68% (48–92) across
all studies. In 30 studies with available data, the mean age was 40
years. All studies reported on patients with a prior history of
treatment. In studies with available data, 84% (32–100) of patients
had previously received anti-tuberculous therapy. The average
MDRTB Outcomes
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reporting resistance. For those reporting first and second-line
resistance, the average number of drugs to which there was
resistance was 4.4.
In the 26 trials with a total 4959 patients reporting EOT
outcomes 62% [95% CI 57–67] of patients met the definition of
successful treatment, while 11% [9–13] of patients died and 8%
[5–11] failed therapy (Table 2). The default rate was 13% [9–17],
while 2% [1–4] had their care transferred to another jurisdiction.
In 9 trials with a total of 1583 patients reporting outcomes at
follow-up, the mean follow-up duration was 27 [15–51] months
(Table 3). The percentage with successful outcomes at follow-up
was 64% [56–72], while 14% [10–19] died, 13% [7–20] defaulted,
5% [2–9] failed therapy, 1% [0–2] had their care transferred and
2 [0–4] relapsed. Based on the data provided, the percentage of
patients presenting with re-infection, rather than relapse cannot be
determined.
Covariate analysis
Predetermined covariates (gender, diabetes, alcohol abuse, HIV
positive, BMI, smear positive, cavitary disease, surgical interven-
tion, prior treatment, $6 drug resistance, fluoroquinolone use,
and presence of XDRTB) were pooled and analyzed. The
following covariates were associated with poor outcome: male
gender (pooled OR for successful outcome 0.61, [95% CI0.46–
0.82]), alcohol abuse 0.49 [0.39–0.63], low BMI 0.41 [0.23–0.72],
smear positivity 0.53 [0.31–0.91], fluoroquinolone resistance 0.45
[0.22–0.91], and XDR resistance pattern 0.57 [0.41–0.80].
Surgical intervention 1.91 [1.44–2.53], no prior TB treatment
1.42 [1.05–1.94] and fluoroquinolone use 2.20 [1.19–4.09] were
associated with successful outcome. Diabetes, cavitary disease,
HIV and resistance to $6 drug were not statistically associated
with worse outcomes. Two covariates, fluoroquinolone use and
XDRTB, were analyzed for an association with death. The use of
fluoroquinolones was associated with decreased mortality 0.30
[0.15–0.61], while there was a trend towards increased mortality
with XDR (Figure 2).
Discussion
Drug resistant TB ultimately develops from the inadequate
treatment of active pulmonary TB. There are multiple reasons for
inadequate therapy; poor prescribing practices with insufficient
treatment duration and poor drug selection are well-recognized
contributors [5,47]. Systemic problems, through inadequate public
health resources and unpredictable drug supplies also play a role
[4]. In addition, irregular medication intake–whether from
Figure 1. Forest plots of covariates.
doi:10.1371/journal.pone.0006914.g001
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determinants–contribute to resistance. There are also a significant
proportion of patients who acquire drug resistant disease because
they live in an environment with a high prevalence of drug resistant
disease.
Despite these well-known causes of drug resistance, our review
of 36 observational studies revealed very high rates of default and
transfer of care. The majority of unsuccessful outcomes at end of
treatment were the result of these factors, with relapse accounting
for only 2% of patients in follow-up. Moreover, default appears to
be a global phenomenon, with rates over 15% in several countries,
including Korea (32%) [25], Taiwan (29%) [15], Russia (20%)
[23], Italy (17%) [18], Spain (16%) [17], South Africa (29%) [35],
Argentina (20%) [33], and Peru (19%) [29]. With the advent of
DOTS and DOTS-Plus strategies, MDRTB rates have improved
in some high prevalence countries, such as Latvia where new
MDR cases have decreased more than two-fold between 2000 and
2007 (V. Leimane, unpublished data). Yet under these improved
circumstances, published default rates were above 10% [27].
The consequences of inadequate therapy are also apparent in
our data. On pooled analysis we have shown that prior treatment,
fluoroquinolone resistance, and XDRTB were all associated with
poor outcomes. While resistance to fluoroquinolones was associ-
ated with worse outcomes, fluoroquinolone use was associated
with successful outcomes. This finding is consistent with several
observational studies showing that fluoroquinolones are highly
effective in MDRTB treatment [15,38,40,45,46,48,49]. The
WHO Green Light Committee recommends that MDR patients
receive a fluoroquinolone when their culture results reveal a
susceptible isolate [10]. But judicious use of fluoroquinolones is
crucial in suspected and confirmed cases of TB if we hope to
impede the development of further resistance [29]. What is less
clear is the role of newer generation fluoroquinolones in the
treatment of fluoroquinolone resistant MDRTB. The findings of
Yew suggest that newer generation fluoroquinolones may be
effective against ofloxacin resistant strains [46]. Further studies will
be necessary to clarify the role of fluoroquinolones in this
population. The emerging XDRTB literature may be a resource
to explore this issue.
Since the seminal report on XDRTB from KwaZulu-Natal,
South Africa [3], multiple studies have reported outcomes of
XDRTB treatment [12,23–26,30,50–53]. In the XDR cohorts
examined in our study, the majority of patients had poor
outcomes, despite low HIV rates. The global burden of XDRTB
reflects the multiple deficiencies of tuberculosis control [47]. With
aggressive, comprehensive individualized therapy, programs can
improve XDRTB outcomes [30]. But, targets for interventions
need to be better defined.
An obvious target for comprehensive interventions is in the
management of co-morbidities. The most commonly reported co-
morbiditiesinourselected studieswere alcoholabuse,lowBMI,and
diabetes. The association between poor outcome with BMI and
alcohol abuse is not unexpected. Body mass index, as a symptom of
severe disease and low socioeconomic status requires aggressive
intervention [29]. To our knowledge, there are no comparative
studies examining the optimal nutritional intervention in an
MDRTB population. Moreover, there are no evidence-based
guidelines on nutritional supplementation in adults or children
[54]. Further studies on MDRTB could not only include a baseline
nutritional intervention, but also study the impact of various
nutritional interventions on MDRTB outcomes. Meanwhile,
alcohol abuse has been associated with poor TB outcome in several
studies [16,23,35,36,55] and measures to improve care for alcohol
abuse should be undertaken. A recently published study in Tomsk,
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e6914Russia, describes successful adoption of a program to address
alcohol use disorders, with the intent to measure outcomes [56].
Diabetes mellitus is also a well-described co-morbidity in
MDRTB patients. Not only are diabetics prone to reactivation
TB [57], they may also be at increased risk of developing MDRTB
[58,59]. The reasons for this are unclear, but based on our pooled
data, diabetics do not appear to have worse outcomes with
MDRTB. These results stand in contrast to previously published
literature on drug sensitive TB [60], and may relate to our small
sample size of 68 diabetics.
Lastly, our data supports the role of surgery in the management
of MDRTB. Surgical patients appear to have superior outcomes—
this may reflect the practice of performing surgery on less sick,
adherent patients who have responded favourably to initial
medical therapy. Although trials in surgery are inherently difficult,
they should be undertaken to examine the role of surgery in
MDRTB patients. Multiple surgical series have been published on
this topic and could be examined for predictors of successful
outcomes. In addition, future trials examining the role of surgery
on highly resistant strains such as fluoroquinolone and XDR
strains may be valuable.
Our study has several limitations. The most important is our
inability to identify any randomized control trials (RCTs). Instead
we relied exclusively on observational data for treatment
outcomes. This likely introduced confounding to our pooled
analysis, since crude outcomes, rather than adjusted odds ratios
were reported for most trials. Moreover, the analysis of outcomes
and pre-determined covariates used heterogeneous data from
variable treatment regimens. The trends introduced by this
analysis are subject to bias and should be interpreted with caution.
Our quality analysis also likely introduced bias since only systems
with resources for record keeping, second-line therapy and
prolonged treatment and follow-up were included for analysis.
These systems likely have improved outcomes compared with the
many poorly resourced TB control programs throughout the
world. Indeed, a recent editorial noted an ‘‘exceptionality’’ bias
when commenting on reported XDRTB outcomes [61].
Of note, our treatment outcome definitions were heterogeneous
between populations. Of the 36 studies included for analysis, only
12 studies (representing nine patient populations) met the outcome
definitions proposed in WHO guidelines [10,16,22–27,30,35,
36,40,41]. The effect of this heterogeneity is difficult to assess.
Table 2. End of Treatment Outcomes.
Author (Reference) Population Successful Outcome Death Default Transfer of Care Failure
Bartu [13] 45 33 11 1 0 0
Chiang [15] 299 153 28 87 0 31
Cox [16] 87 54 13 12 0 8
Escudero [17] 25 21 0 4 0 0
Ferrara [18] 126 49 11 21 16 29
Granich [20] 338 231 49 10 48 0
Hersi [21] 18 8 5 1 4 0
Keshavjee [23] 608 400 31 119 0 58
Kim HR [24] 211 132 19 7 7 46
Kim DH [25] 1407 637 144 453 108 65
Kwon [26] 155 102 10 15 6 22
Leimane [27] 204 135 14 26 0 29
Masjedi [28] 43 29 8 0 0 6
Mitnick 2003 [30] 75 55 5 14 0 1
Narita [31] 81 46 26 9 0 0
O’Riordan [32] 42 25 3 9 4 1
Palmero [33] 141 73 27 28 0 13
Park [34] 142 63 4 41 15 19
Suarez [37] 298 136 32 34 0 96
Telzak [39] 25 16 1 0 0 8
Torun [40] 252 193 18 25 0 16
Tupasi [41] 118 71 18 16 1 12
Uffredi [42] 45 26 12 7 0 0
Van Deun [43] 58 40 8 7 0 3
Ward [44] 44 38 2 3 0 1
Yew [45] 72 51 6 6 0 9
Summary 191 62% 11% 13% 2% 8%
CI [57–67] [9–13] [9–17] [1–4] [5–11]
I
2 91% 80% 94% 93% 94%
P value ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001
doi:10.1371/journal.pone.0006914.t002
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e6914We observed, however, that several studies did not use the
stringent culture-based outcome definitions such as Cure or Failed.
This likely biased results towards more successful outcomes.
Despite this, studies that used WHO outcomes showed similar
outcomes: 62% [5–69] of patients had successful outcomes with a
15% [9–22] default and 10% [7–14] death rate.
Another significant limitation is the lack of data on HIV positive
patients. In total 143 of 6359 patients (2%) were known to be HIV
positive, with the data from 39 patients available for outcome
analysis. This limits the power to detect the effect of the presence
of HIV infection. Some studies reported HIV infected populations
with treatment and follow-up durations shorter than 12 and 18
months respectively [3,62,63]. Thus, our inclusion criteria for
treatment duration and follow-up likely excluded a disproportion-
ate population of HIV positive patients from our analysis. In
addition, our criteria eliminated studies examining ‘outbreaks’ of
MDRTB, where a more virulent strain spreads quickly through a
community. Such outbreak investigations tend to have limited
follow-up and outcome data given the urgency to report findings
[64,65].
Recently, a systematic review examining MDRTB treatment
outcomes in 33 populations was published by Orenstein et al. [66]. In
this review, 62% of patients were classified as successful outcomes.
Covariate analysis revealed that the proportion of patients with
successful treatment outcomes did not significantly change for
several individual covariates. The authors concluded that this
likely reflected study heterogeneity. Similarly, our review exam-
ined MDRTB treatment outcomes. We have, however, focused on
underlying patient and disease characteristics–such as diabetes,
alcoholism, and smear positivity—while, Orenstein et al. focused on
programmatic characteristics such as length of treatment and the
use of Directly Observed Therapy. Overall, our outcomes do not
Table 3. Outcomes at Follow-up.
Author (Reference) Months FUP Sample Size Successful Outcome Death Relapse Transfer of Care Failure Default
Avendano [11] 33 40 28 5 4 0 1 2
Burgos [14] 24 48 31 11 2 3 0 1
Escudero [16] 24 25 21 0 0 0 0 4
Goble [18] 51 159 78 27 0 0 32 22
Mitnick 08 [29] 25 646 412 134 17 0 18 65
Shean [34] 24 491 239 68 0 10 30 144
Van Deun [42] 24 58 35 11 2 0 3 7
Ward [43] 15 44 38 2 0 0 1 3
Yew [44] 25 72 46 8 1 0 4 13
Summary 27 176 64% 14% 2% 1% 5% 13%
CI [56–72] [10–19] [0–4] [0–2] [2–9] [7–20
I
2 87% 74% 80% 70% 85% 91%
p value ,0.0001 0.0002 ,0.0001 0.0009 ,0.0001 ,0.0001
doi:10.1371/journal.pone.0006914.t003
Figure 2. Summary of literature search and study selection.
doi:10.1371/journal.pone.0006914.g002
MDRTB Outcomes
PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e6914differ markedly from those of Orenstein et al., and we feel that our
covariate analysis contributes to the literature on this topic.
Though treatment success remains dismally low in MDRTB
populations, there is reason to be hopeful. With the advent of
standardized nomenclature, outcomes of MDRTB treatment
regimens can be evaluated with more precision. The addition of
more comprehensive therapeutic strategies will also help improve
outcomes. But, an evidence-based approach, in addition to
comprehensive, individualized therapy, is necessary to contain
MDRTB [7]. Without high quality evidence to support therapeu-
tic decisions, including data from high-risk populations such as
HIV positive and diabetic patients, high mortality, default, and
failure rates will persist.
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